High-Tech Gruenderfonds Invests in Startup Computomics

The non-GMO plant breeding industry increasingly uses high-throughput DNA sequencing to arrive at new crop varieties faster and more efficiently. Computomics offers the bioinformatics analysis services required to efficiently use high-throughput sequencing data. Services include genome assembly and annotation, genomic variation, transcriptomics, epigenetics, metagenomics, genomic selection, and phenotyping.

Sebastian J. Schultheiss, managing director at Computomics, describes the origin of the company name: “We apply computational methods to a plethora of –omics data, like genomics and transcriptomics, so we came up with the name Comput-omics.”

In addition to proven expertise and the delivery of reliable results, Computomics’ services feature independence from sequencing platforms and vendors, transparent processes and scientific reproducibility of all analyses. Computomics caters to an international market and already enables three of the top 10 seed manufacturing companies to obtain their new products faster and more efficiently. With the investment, the company will foster its international expansion.

“We are happy to join the company and the enthusiastic team. Sebastian and Tobias and their co-founders are internationally well-known experts in their field. With a strong customer base, we believe that Computomics has the potential to become a global player in ag biotech,” explains Ron Winkler, senior investment manager at High-Tech Gruenderfonds (HTGF).

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

most read